There is a very gray area on when to administer le

There is a very gray area on when to administer lenzilumab. Give it too early and you suppress the immune system completely and only 20-30 percent of people might benefit from it.

Better than nothing, but I’m not sure why people think this drug is anything special. I’ve looked into it and I thought it was sub par? Am I missing something?

IMO it’s not shocking that’s why they teamed up with GILD.

They don’t want Remdesivir to look any worse than it is. Lenzilumab isn’t a threat to their company like Leronlimab.

Lenz is like the red headed step child and Leronlimab is like the golden child.

So not sure what you see on Lenz other than BP is using them to help them sell their crap drug Remdesivir.

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech


— Jeremiah 51:36